Connect with us

Business

Presentation of the annual financial results of Inventivas 2020 Paris Stock Exchange: IVA

Avatar

Published

on



Daix (France), February 23, 2021
Inventiva (Euronext Paris and Nasdaq: IVA), a clinical stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with medical needs major dissatisfied parties, today announced that its management team will host a webcast to present the company’s annual financial results for 2020 on Friday, March 5, 2021.

Inventivas 2020 annual financial results will be released on Thursday, March 4, 2021 at 4:00 p.m. (New York), 10:00 p.m. (Paris).

Frdric Cren, CEO and Co-Founder of Inventiva, Pierre Broqua, Scientific Director and Co-Founder of Inventiva, Jean Volatier, Financial Director of Inventiva, and Michael Cooreman, Medical Director of Inventiva, will organize a conference call in English, followed by a question and answer session, on Friday March 5, 2021 at 8:00 a.m. (New York), 2:00 p.m. (Paris).

The conference call and presentation slides will be webcast live at: https://edge.media-server.com/mmc/p/wr8srgzq and also available on Inventivas in the Investor Financial Results section .

To join the conference call, please use the code 3586531 after dialing one of the following numbers:

France: +33 (0) 1 70 70 07 81
Belgium: +32 (0) 2 793 3847
Germany: +49 (0) 69 2222 2625
Netherlands: +31 (0) 20 795 6614
Switzerland: +41 (0) 44 580 7145
United Kingdom: +44 (0) 207 192 8338
United States: +1 646-741-3167

Please note that the line will be open 10 minutes before the start of the conference call.

A replay of the conference call and presentation will be available after the event at: http://inventivapharma.com/investors/financial-results-presentations/

About Inventiva

Inventiva is a clinical stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical needs.

Leveraging its expertise and experience in compounds targeting nuclear receptors, transcription factors, and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a broad portfolio of early stage programs.

Lanifibranor, its lead product candidate, is in development for the treatment of patients with NASH, a common and progressive chronic liver disease for which there is currently no approved treatment. Inventiva recently announced positive foreground data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH and was granted Breakthrough Therapy and Fast Track designation for lanifibranor in the treatment of NASH.

Inventiva is also developing odiparcil, a second clinical stage active ingredient, for the treatment of patients with subtypes of MPS, a group of rare genetic diseases. Inventiva announced positive foreground data from its Phase IIa clinical trial evaluating odiparcil for the treatment of adult MPS VI patients at the end of 2019 and received FDA Fast Track designation in MPS VI for odiparcil in October 2020.

In parallel, Inventiva is in the process of selecting a candidate for development in oncology for its Hippo signaling pathway program. In addition, the Company has established a strategic collaboration with AbbVie in the area of ​​autoimmune diseases. AbbVie has begun clinical development of ABBV157, a drug candidate for the treatment of moderate to severe psoriasis resulting from its collaboration with Inventiva. This collaboration allows Inventiva to receive milestone payments upon completion of preclinical, clinical, regulatory and commercial milestones, in addition to royalties on any approved product resulting from the collaboration.

The Company has a scientific team of approximately 70 people with in-depth expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, as well as clinical development. It also has an extensive library of approximately 240,000 pharmacologically relevant molecules, of which approximately 60% are proprietary, as well as a 100% owned research and development facility.

Inventiva is a public company listed on compartment C of the regulated market of Euronext Paris (ticker: IVA – ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com


Contacts

  • Inventiva – PR – Invitation to the FY 2020 webcast – 23 02 2021 – EN

What Are The Main Benefits Of Comparing Car Insurance Quotes Online

LOS ANGELES, CA / ACCESSWIRE / June 24, 2020, / Compare-autoinsurance.Org has launched a new blog post that presents the main benefits of comparing multiple car insurance quotes. For more info and free online quotes, please visit https://compare-autoinsurance.Org/the-advantages-of-comparing-prices-with-car-insurance-quotes-online/ The modern society has numerous technological advantages. One important advantage is the speed at which information is sent and received. With the help of the internet, the shopping habits of many persons have drastically changed. The car insurance industry hasn't remained untouched by these changes. On the internet, drivers can compare insurance prices and find out which sellers have the best offers. View photos The advantages of comparing online car insurance quotes are the following: Online quotes can be obtained from anywhere and at any time. Unlike physical insurance agencies, websites don't have a specific schedule and they are available at any time. Drivers that have busy working schedules, can compare quotes from anywhere and at any time, even at midnight. Multiple choices. Almost all insurance providers, no matter if they are well-known brands or just local insurers, have an online presence. Online quotes will allow policyholders the chance to discover multiple insurance companies and check their prices. Drivers are no longer required to get quotes from just a few known insurance companies. Also, local and regional insurers can provide lower insurance rates for the same services. Accurate insurance estimates. Online quotes can only be accurate if the customers provide accurate and real info about their car models and driving history. Lying about past driving incidents can make the price estimates to be lower, but when dealing with an insurance company lying to them is useless. Usually, insurance companies will do research about a potential customer before granting him coverage. Online quotes can be sorted easily. Although drivers are recommended to not choose a policy just based on its price, drivers can easily sort quotes by insurance price. Using brokerage websites will allow drivers to get quotes from multiple insurers, thus making the comparison faster and easier. For additional info, money-saving tips, and free car insurance quotes, visit https://compare-autoinsurance.Org/ Compare-autoinsurance.Org is an online provider of life, home, health, and auto insurance quotes. This website is unique because it does not simply stick to one kind of insurance provider, but brings the clients the best deals from many different online insurance carriers. In this way, clients have access to offers from multiple carriers all in one place: this website. On this site, customers have access to quotes for insurance plans from various agencies, such as local or nationwide agencies, brand names insurance companies, etc. "Online quotes can easily help drivers obtain better car insurance deals. All they have to do is to complete an online form with accurate and real info, then compare prices", said Russell Rabichev, Marketing Director of Internet Marketing Company. CONTACT: Company Name: Internet Marketing CompanyPerson for contact Name: Gurgu CPhone Number: (818) 359-3898Email: [email protected]: https://compare-autoinsurance.Org/ SOURCE: Compare-autoinsurance.Org View source version on accesswire.Com:https://www.Accesswire.Com/595055/What-Are-The-Main-Benefits-Of-Comparing-Car-Insurance-Quotes-Online View photos



picture credit

ExBUlletin

to request, modification Contact us at Here or [email protected]